Can a 3-Week radiation course beat 5 weeks for breast cancer patients with reconstruction?

NCT ID NCT07084519

Recruiting now Disease control Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial tests whether a shorter, higher-dose radiation schedule (3 weeks) is as safe and effective as the standard 5-week schedule for women with high-risk breast cancer who have had a mastectomy and immediate implant reconstruction. The study will enroll 506 women and track reconstruction failure, side effects, and cancer recurrence. The goal is to see if the shorter course can reduce treatment time without increasing complications.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: radiation therapy (hypofractionated or conventional)
What this could lead to: If successful, a shorter 3-week radiation course could become the new standard, reducing treatment burden and possibly lowering complication rates for women with breast reconstruction.
What could go wrong: This is still a recruiting phase 3 trial; results may show no benefit or higher reconstruction failure with the shorter regimen. Individual outcomes vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast adenocarcinoma breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER BREAST RECONSTRUCTION RADIATION ONCOLOGY

Contacts and locations

Locations

Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
RECRUITING

Beijing, Province, 10000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.